Tekla Capital Management LLC bought a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 117,717 shares of the company’s stock, valued at approximately $2,996,000. Tekla Capital Management LLC owned approximately 0.20% of […]
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) have been given an average recommendation of “Moderate Buy” by the eight research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year […]
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Get Rating) – Research analysts at HC Wainwright dropped their Q2 2023 earnings estimates for Syndax Pharmaceuticals in a report issued on Tuesday, May 9th. HC Wainwright analyst E. White now expects that the company will post earnings per share of ($0.70) for the quarter, down from their prior forecast […]
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) had its target price raised by HC Wainwright from $33.00 to $36.00 in a research report released on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q2 2023 earnings at ($0.70) EPS, Q3 2023 earnings at ($0.83) EPS, Q3 2023 earnings at ($0.83) EPS, […]
Syndax Pharmaceuticals (NASDAQ:SNDX – Get Rating) had its target price hoisted by HC Wainwright from $33.00 to $36.00 in a research note released on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Syndax Pharmaceuticals’ Q2 2023 earnings at ($0.70) EPS, Q3 2023 earnings at ($0.83) EPS, Q3 2023 earnings at ($0.83) EPS, […]